Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
By R. Pratley, M. Nauck, T. Bailey, E. Montanya, R. Cuddihy, Sebastiano Filetti, A. B. Thomsen, Rie E Søndergaard, M. Davies. The Lancet, 2010
610 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Surgery
View Paper: https://www.semanticscholar.org/paper/f2386a7c0bafab4f8c4760d09e6c8c14e2baaa12
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Surgery
Citations in the corpus
- Mechanisms of diabetic complications. (2013, background): “namely, sulfonylureas (612) and the glucagon-like peptide-1 (GLP-1) agonists (225) and dipeptidyl peptidase-IV (DPPIV) inhibitors (472), are also widely used in clinical practice to address the relative insulin deficiency seen in the context of concomitant insulin resistance.”